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RCAN1 is a chromosome21gene that controls secretion in endocrine cells, regulatesmitochondrial
function, and is sensitive to oxidative stress. Regulator of calcineurin 1 (RCAN1) is also an endog-
enous inhibitor of the protein phosphatase calcineurin, the inhibition of which leads to hypoin-
sulinemia and diabetes in humans and mice. However, the presence or the role of RCAN1 in
insulin-secreting -cells and its potential role in the pathogenesis of diabetes is unknown. Hence,
the aim of this study is to investigate the presence of RCAN1 in -cells and identify its role in -cell
function.RCAN1 is expressed inmouse islets and in the cytosol of pancreatic-cells.We findRCAN1
is a glucose-responsive gene with a 1.5-fold increase in expression observed in pancreatic islets in
response to chronic hyperglycemia. The overexpression of the human RCAN1.1 isoform in mice
under the regulation of its endogenous promoter causes diabetes, age-associated hyperglycemia,
reduced glucose tolerance, hypoinsulinemia, loss of -cells, reduced -cell insulin secretion, aber-
rant mitochondrial reactive oxygen species production, and the down-regulation of key -cell
genes. Our data therefore identifies a novel molecular link between the overexpression of RCAN1
and -cell dysfunction. The glucose-responsive nature of RCAN1 provides a potential mechanism
of action associated with the -cell dysfunction observed in diabetes. (Endocrinology 153:
5212–5221, 2012)
Diabetes is a metabolic disorder characterized by ele-vated fasting blood glucose, which arises when insu-
lin-secreting-cells cannot provide adequate insulin in the
face of increasing insulin resistance. The pancreatic -cell
is the central regulator of glucose homeostasis and the
primary source of endogenous insulin. Two major forms
of diabetes exist, type 1 and type 2. Type 1 diabetes results
from the autoimmune destruction of -cells, whereas type
2 diabetes is associated with obesity, peripheral insulin
resistance, and gradual insulin insufficiency. Increased
levels of glucotoxicity in -cells are thought to be central
to the pathogenesis of-cell dysfunction in type 2 diabetes
(1), but the exact nature of the molecular mechanisms
underlying -cell dysfunction in the presence of insulin
resistance and hyperglycemia is unknown. Candidate
genes that might trigger -cell dysfunction under such cir-
cumstances would need to have their expression induced
by hyperglycemia and have potential roles in the regula-
tion of -cell function.
RCAN1 is located on chromosome 21 within the
q22.1–q22.2 region. The seven exons within the RCAN1
gene give rise to two regulator of calcineurin 1 (RCAN1)
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isoforms, the longer and more abundant RCAN1.1 iso-
form and the shorter and lowly expressed RCAN1.4 iso-
form. Expression ofRCAN1 is highest in brain, heart, and
skeletal muscle (2). RCAN1 expression is induced by a
number of stress-associated stimuli including Ca2, am-
yloid- and oxidative stress (3). Oxidative stress is prev-
alent in -cells exposed to hyperglycemia (4), and this is
due to the low expression levels of endogenous antioxi-
dant systems in these cells.
The most well-defined function of RCAN1 is as an in-
hibitorof thephosphatase calcineurin (5–9), the activityof
which is central to normal -cell function and plasma in-
sulin levels (10). Increased RCAN1 negatively affects the
secretion of catecholamines from adrenal chromaffin cells
(11) andmitochondrial function in neurons (12) aswell as
cell proliferation and tissue growth (13, 14). It is worth
comparing these functions with the compromised -cell
insulin secretion, mitochondrial function, islet growth,
and -cell proliferation that are all observed in type 2
diabetes (15). Hyperglycemia-induced oxidative stress is
thought to be central to -cell dysfunction in type 2 dia-
betes (15), and oxidative stress induces RCAN1 expres-
sion (3). The combination of these facts suggests that ab-
errant RCAN1 function in -cells may have implications
in the pathogenesis of -cell failure in type 2 diabetes.
Based on its known roles in regulating secretion, mito-
chondrial function, calcineurin activity, and cell prolifer-
ation, we investigated the role of RCAN1 in -cell func-
tion. Our findings demonstrate that the overexpression of
RCAN1 in mice causes diabetes characterized by hypoin-
sulinemia and -cell dysfunction via multiple pathways.
Materials and Methods
Animals
RCAN1 transgenic (RCAN1ox) mice were generated using
human RCAN1 cDNA encoding the exon 1 splice variant as
described (11). The minigene transgene construct consisted of a
4-kb region up-stream of exon 1 and also contained exons 5–7
and their flanking introns. The minigene DNAwas prepared for
microinjection by a double digestionwithHindIII andNotI, and
the gel-purified insert was used to microinject fertilized mouse
embryos of C57:B6  CBA genetic background. The gene con-
struct was under the regulation of its endogenous promoter. The
wild-type (WT) mice were of C57:B6  CBA genetic back-
ground.WTandRCAN1oxmiceweremaintained in the Flinders
University Animal House under pathogen-free conditions in a
12-h light, 12-h dark cycle, and usewas approved by the Flinders
University Animal Welfare Committee. Male mice were used in
all studies.
Fasting blood glucose measurement
Fasting blood glucose levels were measured at the ages indi-
cated. Beforemeasurement,micewere transferred to a fresh cage
without food for 16 h. All mice had access to water ad libitum
during this period. Samples were obtained at the ages indicated.
Bloodwas sampled from the tail, and fasting blood glucose levels
were measured using an ACCU-CHEK Performa glucometer
(Roche Diagnostics, Castle Hill, Australia).
Isolation of mouse pancreatic islets
Mice were killed by an anesthetic overdose of isoflurane and
islets isolated as previously described (16).
Quantitative real-time PCR
RNAwas extracted frommouse islets using the RNeasyMini
Kit (QIAGEN, Doncaster, Australia). Real-time PCR was car-
ried out using the QIAGEN Quantitect SYBR Green PCR kit
(QIAGEN, Australia) and RotorGene 3000 thermocycler (Cor-
bett Life Science, Sydney, Australia). All real-time experiments
were carried out using 3 l of diluted cDNA. The 18s rRNA
primer sets were used as the housekeeping gene to normalize
samples and evaluate changes in expression. A sample with a
no-cDNA template was the negative control. All samples were
run in triplicate. Primer sequences and other information for all
target genes are provided in Supplemental Table 1 (published on
The Endocrine Society’s Journals Online web site at
http://endo.endojournals.org).
Immunoblot analysis of RCAN1
Immunoblot analysis of RCAN1 was performed using anti-
RCAN1 antibodies at a dilution of 1:200 (Sigma-Aldrich, St.
Louis, MO). Proteins were extracted in RIPA buffer containing
0.1% SDS using a tissue-lyser (QIAGEN, Australia). Protein
concentration was estimated using the EZQ assay (Invitrogen,
Australia). 25 g of each sample was separated on a Criterion
TGX stain-free gel (Bio-Rad, Australia) and transferred onto
0.2-m polyvinylidene fluoride membrane (Roche Applied Sci-
ence, Australia). Blots were probed using a donkey antirabbit-
horseradish peroxidase-conjugated secondary antibody at a di-
lution of 1:100 (Thermo Scientific) andWest Pico (Pierce) as the
substrate for chemiluminescent detection. Blots were visualized
on a Fujifilm LAS4000 and Gel Doc Ez-Imagers (Bio-Rad, Aus-
tralia). Densitometry was performed with Carestream Molecu-
lar Imaging Software (Carestream Health).
Insulin measurements
Blood insulin levels weremeasured after 16 h fasting using an
ultrasensitive mouse insulin ELISA kit (Crystal Chem Downers
Grove, IL) according to the manufacturer’s instructions for a
low-range assay (17) Absorbance was measured at 450 and 620
nm using a BIOMECK-3000 microplate reader (Beckman-
Coulter Brea, CA) and MultiMode detection software. For in
vitro glucose-stimulated insulin secretion (GSIS), 10 islets were
incubated in 50 l of Krebs buffer (supplemented with 3 mM
glucose) at 37 C for 1 h (basal secretion). Islets were exposed to
Krebs buffer with 20 mM glucose for 10 min (first-phase GSIS)
and 50 min (second-phase GSIS). Islets were allowed to recover
for 1 h at 3 mM glucose before being exposed to a high-K (70
mM) Krebs solution for 20 min. Samples were centrifuged at
250 g for 1min, the supernatant removed, and insulin content
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measured as described previously. To measure islet insulin con-
tent, 10 islets were subjected to 12 freeze-thaw cycles in RIPA
buffer and centrifuged at 250 g for 1min.The supernatantwas
diluted 1:1000 in PBS and insulin content measured by ELISA.
Glucose tolerance test
Glucose tolerance tests were carried out on mice fasted for
16 h. Glucose (2mg/g bodyweight) (PharmaLab, Australia) was
injected (ip) into mice and blood glucose measured at 15-min
intervals from 0–240min via a tail bleed using anACCU-CHEK
Performa glucometer (Roche Diagnostics, Australia).
Immunohistochemical labeling in pancreatic
sections and MIN6 cells
Whole pancreatic tissue was fixed in 10% buffered formalin
for 24 h after excision from the animal. Tissue was then washed
in PBS (pH7.2) supplementedwith sodiumazide for 2h and then
washed in running deionized water for 2 h. The tissue was sub-
sequently dehydrated in ethanol (80, 90, and 100% for 2 h in
each solution) and then transferred to chloroformovernight.The
tissue was embedded in Paraplast wax for 1 h (62 C) and fresh
wax for 1.5 h and finally embedded in fresh wax. The 5-m
sectionswere allowed todryovernight in a37Coven.Guineapig
polyclonal antibody to insulin (AbCam, Cambridge, MA) was
used diluted 1:3200 in antibody diluent [NaCl, Na2HPO4,
Na2HPO42H2O,10%NaN3 indistilledwater (pH7.1)]. Biotin-
streptavidin-conjugated donkey anti-guinea pig secondary anti-
body (Jackson ImmunoResearch,WestGrove, PALaboratories)
was used at a dilution of 1:200 and labeledwith Cy3-conjugated
streptavidin (Jackson Laboratories), and 3 M 4,6-diamino-2-
phenylindole, dihydrochloride (DAPI) (Invitrogen, Australia)
was used as a nuclear marker.
MIN6 -cells were grown for 24 h on glass coverslips coated
with 10 g/ml poly-D-lysine and 10 g/ml laminin (Sigma-Al-
drich) and in DMEM containing 10% FBS, 1% penicillin-strep-
tomycin (1 mg/ml), 1% L-glutamine, and 5 l/liter ß-mercapto-
ethanol (Sigma-Aldrich). Cells were fixed for 18–20 h in
Zamboni’s fixative at 4 C followed by washes in 80% ethanol
(four times for 5min each), 100%ethanol (twice for 5min each),
dimethylsulfoxide (three times for 5 min each), and PBS (four
times for 5 min each). Fixed cells were incubated for 30 min in
10%normal donkey serum, placed for 24h at room temperature
in a humidifier with rabbit monoclonal antibody against
RCAN1 (Sigma-Aldrich) (final dilution 1:10) and guinea pig
monoclonal antibody against insulin (Abcam) (final dilution
1:3200). The cells were washed with PBS and incubated in don-
key antirabbit IgG-Cy5 (Jackson Immunoresearch) (final dilu-
tion 1:400) and donkey anti-guinea pig IgG taggedwithCy3 and
DAPI as described in the previous paragraph.Afterwashingwith
PBS, the coverslips were mounted onto glass slides in buffered
glycerol and fluorescence visualized on a Leica TCS SP5 Spectral
confocal microscope.
Measurement of islet size and -cell density
Islet size was determined by measuring the insulin-positive
area of individual islets in paraffin embedded pancreatic sec-
tions. -cell density of an islet was measured by counting the
number ofDAPI-positive cells per islet area.Analysiswas carried
out on ImageJ image analysis software. 8–10 islets were mea-
sured from each animal.
Insulin tolerance test
Insulin tolerance testswere carried onmice fasted for 1 h, and
0.75 or 1 U/kg body weight insulin (Novo Nordisk, Australia)
was injected (ip) into40- and120-d-oldmice, respectively. Blood
glucose wasmeasured via a tail bleed from 0–120min at 15-min
intervals using an ACCU-CHEK Performa glucometer (Roche
Diagnostics, Australia).
Islet reactive oxygen species (ROS) production
After isolation, islets were allowed to recover overnight in
phenol red-free RPMI (10% heat inactivated fetal calf serum).
Isletswere transferred intomedia supplementedwith 20 or 5mM
glucose (control) for 24 h. Islets were incubated with 5 M Mi-
toSox Red (Invitrogen, Australia) for 10 min, washed twice in
Krebs solution, and visualized on an IX-71 fluorescent micro-
scope (Olympus, Japan). Mean fluorescence intensity of indi-
vidual islets was calculated using ImageJ image analysis soft-
ware. Seven to 10 islets were measured from each animal.
Electron microscopy studies
The pancreas was cut into cubes of approximately 0.5 mm3
and processed for electronmicroscopy as reported (18). Sections
were examined using a Hitachi H-600 transmission electron mi-
croscope (Tokyo, Japan).-Cellswere distinguished from- and
-cells by the presence of their characteristic granules as de-
scribed in previous studies (18). Insulin secretory vesicle density
was calculated by counting the number of large dense-core ves-
icles (LDCVs) per cell and normalized to cell area. To measure
vesicle localization, 200-nm-wide concentric zones starting from
the cell membrane were defined within each -cell and the num-
ber of dense core vesicles within each region counted and pre-
sented as a percentage of the total number of vesicles within each
cell. Filled secretory vesicles containing insulinwere clearly iden-
tified by the presence of a dense core within the vesicle. Empty
secretory vesicles were identified as being a membrane-bound
vesicle in the range of 100–300 nm in diameter, the same size
range as that found for filled vesicles. All analysiswas carried out
on 4000 electron micrographs using ImageJ image analysis
software.
Statistical analysis
Parametrically distributed data were analyzed using an un-
paired Student’s t tests and for nonparametric data sets aMann-
Whitney U test was used. Statistical significance was P  0.05.
All data are shown as mean  SEM.
Results
RCAN1 is a glucose-responsive gene present in -
cells that regulates the expression of islet gene
products
To study the role of RCAN1 in -cell function, we con-
firmed the presence of theRCAN1 gene in mouse pancre-
atic islets and MIN6 -cells (Fig. 1A). Using immunohis-
tochemistry, we also observed a largely cytoplasmic
expression of RCAN1 protein in MIN6 -cells (Fig. 1B).
Chronic high glucose is thought to induce oxidative stress
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in -cells, leading to -cell dysfunction and -cell loss in
type 2 diabetes. Because oxidative stress induces RCAN1
expression, we hypothesized that chronic high glucose ex-
posure would induce -cell RCAN1 expression. Using
real-time PCR (Fig. 1C) and Western blotting (Fig. 1D),
we found that in vitro islet RCAN1 expression is induced
by chronic (6 d) hyperglycemia. To study the effect of
RCAN1 overexpression on glucose homeostasis and
-cell function, we used mice in which human RCAN1.1
is overexpressed (RCAN1oxmice) (11).Overexpressionof
RCAN1 in thesemiceoccursonly in cells inwhichRCAN1
is endogenously expressed. These mice are viable and fer-
tile and display no overt phenotype. Blood analysis indi-
cates no change inmarkers associatedwith liver or kidney
function or in cholesterol, triglyceride, or high-density li-
poprotein levels (data not shown) when RCAN1ox mice
are compared with controls. The overexpression of
RCAN1.1 was confirmed in pancreatic islets of wild-type
and RCAN1ox mice (Fig. 1E). RCAN1 protein levels in
pancreatic islets of RCAN1ox mice at 40 and 120 d of age
also confirmed the overexpression of RCAN1.1 (Fig. 1F).
Because the calcineurin/nuclear factor of activated T-cells
pathway is a known regulator of -cell gene expression
(10) and RCAN1 inhibits calcineurin activity, we tested
whether important -cell genes are regulated by RCAN1
overexpression.We identifiedmultiple gene targets down-
regulated in RCAN1ox islets (Fig. 1G). These include
Hnf1,Hnf1,NeuroD1, and glucokinase, mutations in
which causemonogenic forms of type 2 diabetes knownas
maturity-onset diabetes of the young (MODY). These are
each regulated by the calcineurin/nuclear factor of acti-
vated T-cells pathway (10). Additionally, the expression
of the transcription factor ARNT and its cofactor AhR,
implicated in-cell dysfunction in type 2diabetes (19), are
FIG. 1. RCAN1 is expressed in -cells where it is responsive to hyperglycemia and regulates the expression of essential -cell gene products. A,
RCAN1 is endogenously expressed in mouse islets and -cells. PCR using mRNA isolated from islets and the MIN6 -cell line and primers specific to
exon 7 of the RCAN1 genome illustrates RCAN1 expression. B, RCAN1 protein expression is cytoplasmic in mouse MIN6 -cells; from left to right,
bright-field image of MIN6 cells, insulin (red), RCAN1 (green), and merged image of insulin, RCAN1, and DAPI (blue). C and D, Real-time RT-PCR
(C) and Western blot analysis (D) in WT islets illustrates that chronic (6 d) hyperglycemia induces islet RCAN1 expression. E, Real-time RT-PCR was
performed on isolated islets from 120-d-old WT and RCAN1ox mice. F, Western blot analysis illustrates RCAN1 expression in WT islets and RCAN1
overexpression in RCAN1ox islets at 40 d (lane 1 and 2) and 120 d (lane 3 and 4). G, Real-time RT-PCR was performed on isolated islets from WT
and RCAN1ox mice for -cell gene products. White bars, WT; black bars, RCAN1ox (n  5 animals per genotype). *, P  0.05.
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both reduced in RCAN1ox islets. The expression of genes
encoding theglucose transporter2and the insulin receptor
are also reduced. Ins-1 expression is not altered, in agree-
ment with the lack of change in total insulin content we
observe in RCAN1ox islets (see Fig. 4B). We also observe
an increased expression of the apoptotic markers
caspase-3 and caspase-9 in RCAN1ox islets (Fig. 1G).
RCAN1ox mice develop diabetes
RCAN1ox mice develop increasingly severe hypergly-
cemia and overt diabetes from 60 d of age compared with
age-matched WT controls (Fig. 2A). This is not due to
increased body weight in RCAN1ox mice (Fig. 2B). Glu-
cose tolerancewas assessed by ip glucose tolerance tests at
two different ages, before and after the onset of hypergly-
cemia in RCAN1ox mice. Glucose tolerance was un-
changedat40d (Fig. 2C), butRCAN1oxmicedemonstrate
impaired glucose tolerance at 120 d (Fig. 2D). The hyper-
glycemiaobserved inRCAN1oxmice is likely caused either
by increased insulin resistance or by decreased plasma in-
sulin levels. To identify whether such changes occur, we
measured insulin resistance in RCAN1ox mice. No signif-
icant difference in blood glucose between WT and
RCAN1ox mice was observed at any of the time points in
response to the injected insulin at both 40 d (data not
shown) and 120 d of age (Fig. 2E). However, when we
transform these results into relative changes in insulin-
induced blood glucose (Supplemental Fig. 1), we see that
RCAN1oxmice have increased sensitivity to an exogenous
insulin load at 120 d. Thus, RCAN1ox mice may develop
an increased response to a given amount of insulin as they
age, andRCAN1oxmice clearly donot develop any insulin
resistance. The absence of insulin resistance in RCAN1ox
mice suggests that hypoinsulinemia may underlie the age-
associated diabetes observed in RCAN1ox mice. Consis-
tent with this, circulating insulin levels were significantly
lower at 120 d in RCAN1ox mice (Fig.
2F).
RCAN1 regulates islet morphology
and -cell number
To identifywhether this reduction in
circulating insulin could be caused by a
loss of -cells, we stained pancreatic
sections for insulin (Fig. 3A) and mea-
sured total -cell mass per islet. Islet
size was significantly smaller in
RCAN1ox mice at 100 d (P  0.001)
but not at 40 d (Fig. 3B). Islet shrinkage
was due to a reduction in total -cell
number per islet (Fig. 3C) rather than
decreased -cell size (Fig. 3D).
RCAN1 regulates insulin secretion
and insulin loading in -cells
Given the reductions in circulating
insulin levels and -cell number in
RCAN1ox mice, we next wished to
identify whether elevated RCAN1 ex-
pression affects insulin secretion. Static
in vitro islet insulin secretion (normal-
ized to total islet protein content to
compensate for variations in islet size)
was measured to gauge -cell secretory
capacity. Basal (P  0.05) and first-
phase (10 min, P  0.05) GSIS were
both reduced in RCAN1ox islets,
whereas second-phase secretion
(10–60 min after glucose stimulation)
wasnotaltered (Fig. 4A).The reduction
FIG. 2. RCAN1ox mice develop diabetes. A, RCAN1ox mice (black bars) have higher fasting
blood glucose levels from 60 d compared with WT controls (white bars). B, Body weight is
similar in WT (white bars) and RCAN1ox mice (black bars) at all ages. C and D, Glucose
tolerance is similar between groups at 40 d (C) but is reduced in RCAN1ox mice at 120 d of
age (D) (n  5–10 animals per genotype). *, P  0.05. White squares, WT; black squares,
RCAN1ox. E, The 120-d-old mice were injected ip with insulin (1 U/kg body weight) and blood
glucose measured at times indicated. No differences in glucose level were observed between
the two groups. F, Fasting blood insulin is similar at 40 d but significantly lower in RCAN1ox
mice at 120 d.
5216 Peiris et al. RCAN1 Controls -Cell Function Endocrinology, November 2012, 153(11):5212–5221
Archived at Flinders University: dspace.flinders.edu.au
in secretory capacitywas not due to decreased insulin con-
tent within pancreatic islets (Fig. 4B). Electron micro-
scopic analysis of -cells was carried out to investigate
potential mechanisms underlying the
insulin secretion defect. Electron mi-
crographs ofWT andRCAN1ox-cells
clearly identified both filled and empty
large vesicles (Fig. 4C). Analysis of
these images reveals that the number of
empty vesicles (Fig. 4D), but not insu-
lin-containing LDCVs (Fig. 4E), was
significantly higher in RCAN1ox
-cells. The proximity of insulin-con-
taining LDCVs to the plasma mem-
brane was unchanged in RCAN1ox
-cells (Fig. 4F). The number of docked
vesicles (filled vesicles in contact with
the plasma membrane) was also un-
changed in RCAN1ox -cells (Fig. 4G).
Because RCAN1 overexpression caused an increase in
empty vesicles, we hypothesized that the filling of LDCVs
might be negatively affected in
RCAN1ox -cells. We detected a small
(8%) but significant reduction in the
diameter of the dense core (containing
insulin) within LDCVs in RCAN1ox
-cells (111.0  1.6 nm) compared
with WT -cells (120.8 1.8 nm, P
0.01) (data not shown), indicating re-
duced insulin loading into RCAN1ox
LDCVs. This is not due to a concomi-
tant reduction in total LDCV diameter
in RCAN1ox -cells (data not shown).
RCAN1 affects mitochondrial
morphology and function
Mitochondrial changes and in-
creased ROS production are observed
in -cells from type 2 diabetes patients
(15) and upon overexpression in neu-
rons of the Drosophila melanogaster
RCAN1 ortholog nebula (12). The ul-
trastructural appearance of mitochon-
dria is unchanged in RCAN1ox -cells
(Fig. 5A).Although the samenumberof
mitochondria were seen in each group
(Fig. 5B), mitochondrial size was re-
duced in RCAN1ox -cells (P  0.05,
Fig. 5C). Hyperglycemia-induced oxi-
dative stress reducesmitochondrial size
(20).We thereforemeasuredmitochon-
drial ROS production in WT and
RCAN1ox islets using the mitochon-
drial ROS marker MitoSox (Fig. 5D).
Basal (3 mM glucose) mitochondrial
FIG. 3. RCAN1 regulates islet morphology and -cell number. A, Pancreatic sections were
labeled with an antiinsulin antibody (red) and nuclear marker DAPI (blue) to measure islet size.
Scale bar, 50 m. B–D, Islet size was similar between groups at 40 d but significantly smaller
in RCAN1ox mice at 100 d (B) because there are fewer -cells per islet in RCAN1ox mice (C)
and not due to any change in -cell size at 120 d as measured from electron microscopy
images (D). *, P  0.05; ***, P  0.001; n  5–9 animals per genotype. Black bars, RCAN1ox
mice; white bars, WT mice.
FIG. 4. RCAN1 regulates insulin secretion and vesicle loading in -cells. A, Insulin secretion is
compromised in RCAN1ox -cells. Basal (3 mM glucose for 1 h) and first-phase (time 0–10 min
in 20 mM glucose) insulin secretion are significantly reduced in RCAN1ox islets, whereas second-
phase (time 10–60 min in 20 mM glucose) secretion is not altered (n 5 mice sampled in
triplicate per group). B, Total insulin content of islets is unaltered (n 13–15). C, Electron
micrographs of a WT (left) and RCAN1ox (right) -cell demonstrate the presence of both filled and
empty (arrows) secretory vesicles within the cytosol of -cells. D and E, The number of empty
secretory vesicles (D) but not filled vesicles (E) is increased in RCAN1ox -cells. F and G, We did not
observe differences in the proximity of insulin-containing vesicles to the plasma membrane (F) or
the number of docked vesicles (G) (n 3–5 animals and 6–8 -cells per genotype). *, P 0.05.
White bars, WT; black bars, RCAN1ox. Scale bar, 500 nm (C).
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ROSproduction in islets was similar between both groups
(Fig. 5E). After exposure to 20 mM glucose, WT islets
displayed moderately increased mitochondrial ROS
production (P 0.05), consistent with previous reports
(4). However glucose-induced increase in mitochon-
drial ROS production was greater in RCAN1ox islets
(P  0.001, Fig. 5E), illustrating RCAN1-induced mi-
tochondrial dysfunction.
Discussion
Normal -cell function and insulin secretion are essential
for the regulationof circulatingplasmaglucose levels.This
current study identifies theRCAN1 gene as being involved
in the proper control of glucose homeostasis due to its
effect on multiple facets of -cell function. We further
identify RCAN1 as a glucose-regulated gene that has in-
creased expression in islets under glucotoxic conditions.
We demonstrate that when RCAN1 expression is in-
creased in vivo in mice, the result is the development of
diabetes associated with -cell failure. InRCAN1ox mice,
age-dependent hyperglycemia, impaired glucose toler-
ance, hypoinsulinemia, reduced -cell secretion, reduced
-cell number, decreased insulin granule filling, aberrant
mitochondrial ROS production, and the altered expres-
sion of key -cell genes occur. Thus, RCAN1 is an impor-
tant -cell gene, regulating multiple facets of -cell
function.
The experiments used mice in which RCAN1 is over-
expressed in all cells that normally express RCAN1.
Hence, the interpretations of our work cannot be solely
confined to effects of RCAN1 directly on -cells. Al-
though studies have shown the presence of RCAN1 in the
exocrine acinar cells of the pancreas (21), it is currently
unknown whether RCAN1 is present in the endocrine -
and -cells of the pancreatic islet. Furthermore, we ob-
served no overt changes in liver or kidney function or
changes in blood lipids or in body weight. These results
also demonstrate that RCAN1ox mice are not insulin re-
sistant but rather show an increased response to insulin at
100 d.What underlies this increase in insulin sensitivity is
unknown. Itmay be due to an undescribed role ofRCAN1
in regulating insulin sensitivity in peripheral tissues in
which it is expressed, such as skeletal muscle or liver (2).
Alternatively, this change in insulin sensitivity may reflect
a physiological adjustment by RCAN1oxmice in response
to the lower levels of circulating insulin to maintain glu-
cose homeostasis and minimize hyperglycemia. Many of
our in vitro studies were also performed using isolated
islets to alleviate concerns regarding non--cell effects of
elevatedRCAN1expression.These isletsweremaintained
in culture for several days before experimentation, poten-
tially removing any indirect in vivo effects that could po-
tentially occur inRCAN1oxmice.This tissuewasobtained
at an age inwhich thesemice are hyperglycemic, and there
is the additional possibility that hyperglycemia may be
driving some of the -cell changes we observed, such as
aberrant ROS production, gene expression changes, and
reduced insulin secretion. If in vivohyperglycemiawas still
affecting in vitro islet function, however, higher resting
ROS levels would have been observed in RCAN1ox islets.
Becausewe do not observe such changes, we are confident
that the 72- to 96-h culture period used in our in vitro
FIG. 5. RCAN1 regulates mitochondrial size and ROS production. A, Electron micrographs of WT (left) and RCAN1ox (right) -cell mitochondria
illustrating similar mitochondrial appearance. B and C, Mitochondrial density (B) is similar, whereas mitochondrial size (C) is smaller in RCAN1ox
-cells (n  3 animals per genotype, n  6–8 -cells and 170–208 mitochondria). D, MitoSox fluorescence in WT and RCAN1ox islets under
various conditions. E, Mitochondrial ROS production is greater in response to 20 mM glucose in RCAN1ox islets; n  3 individual islet preparations
and 20–32 islets. *, P  0.05; **, P  0.01; ***, P  0.001. Scale bar, 500 nm (A) and 200 m (D).
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experiments is sufficient to remove potential confounding
effects of hyperglycemia in RCAN1ox islets.
The diabetes associatedwithRCAN1overexpression is
due to hypoinsulinemia caused by -cell loss and dysfunc-
tion. One mechanism associated with this -cell loss may
be increased apoptosis, as indicated by the elevated ex-
pression of the apoptosis gene markers capsase-3 and
caspase-9 in RCAN1ox islets. Overexpression of
RCAN1.1 in primary neurons activates both caspase-9
and caspase-3, which induces neuronal apoptosis (22).
This neurotoxic effect ofRCAN1.1 is inhibited in caspase-
3/ neurons, indicating the potential for RCAN1 to in-
duce -cell apoptosis via this enzyme (23). The large in
vitro increase in ROS production under hyperglycemic
conditions in RCAN1ox islets illustrates that in vivo oxi-
dative stress is likely higher in RCAN1ox islets once
RCAN1oxmice become diabetic. Oxidative stress induces
apoptosis in -cells and reduces -cell proliferation (24).
Additionally, loss of calcineurin function reduces -cell
proliferation (10) and loss of NeuroD function, which is
down-regulated in RCAN1ox islets, reduces -cell gener-
ation, and increases apoptosis (25). The loss of -cells in
RCAN1oxmicemay also be indirectly due to the effects of
hyperglycemia itself. Chronic hyperglycemia has a clear
link to increased -cell apoptosis and reduced prolifera-
tion (26).Therefore, severalmechanismsmayexplainhow
RCAN1 overexpression results in loss of -cells.
Not only are -cells lost as RCAN1ox mice age but the
secretory capacity of remaining RCAN1ox -cells is also
reduced. The negative effect of RCAN1 on insulin release
is not due to reduced insulin synthesis or altered localiza-
tion of insulin granules or vesicle docking at the plasma
membrane. The smaller size of the insulin granules in
RCAN1ox -cell LDCVs and increase in the number of
empty vesicles indicates problems with vesicle loading.
The ZnT-8 vesicle zinc transporter controls insulin load-
ing into vesicles and is inhibited by calcineurin inactivity
andRCAN1 overexpression (27). Although this could ex-
plain the smaller insulin granule size and higher number of
empty vesicles in RCAN1ox -cells, these effects are rela-
tively minor.
Basal insulin release and first-phase GSIS are each re-
duced in RCAN1ox -cells, similar to secretory defects
occurring in islets isolated from type 2 diabetes patients
(28). RCAN1 may affect distal steps in the exocytosis
pathway as occurs in RCAN1ox adrenal chromaffin cells
in which the number of exocytotic events and the amount
released per vesicle are reduced (11).However, this would
not explain the specific decrease in first-phase, but not
second-phase, GSIS. KATP channel-dependent mecha-
nisms drive first-phase GSIS (29), whereas KATP channels
are required only as an initiating event in the sustained
second-phase insulin response (30). The reduced Glut2
and glucokinase expression in RCAN1ox islets may limit
glucose 6-phosphate availability for oxidative phosphor-
ylation and glucose-regulated KATP channel closure and
potentially explain reduced first-phase GSIS.Whether the
overexpression of RCAN1 affects oxidative phosphory-
lation andKATP channel function resulting in altered first-
phase but normal second-phase insulin secretion is unre-
solved and will be a matter of future study.
RCAN1ox-cellmitochondria are smaller andproduce
more ROS in vitro when exposed to high glucose. In-
creased RCAN1 expression in Drosophila neurons pro-
motes mitochondrial fission and ROS production (12),
and hyperglycemia increases mitochondrial fission
through increased expression of dynamin-related protein
1 (31). Under conditions of chronic high glucose or free
fatty acid exposure, -cell mitochondria lose their ability
to undergo fusion that would otherwise prevent -cell ap-
optosis under such conditions (32). From the present
study, we cannot conclude whether elevated RCAN1 ex-
pression directly reduced mitochondrial size or whether
the aberrantly high hyperglycemia-induced ROS levels
present inRCAN1ox-cells is the cause.Our data raise the
interesting possibility that RCAN1 may act as a link be-
tween hyperglycemia, mitochondrial fission, ROS pro-
duction, and -cell apoptosis. Greater glucose-stimulated
ROS production in RCAN1ox islets than inWT islets was
also observed. Glucose normally enters the glycolytic
pathway and preferentially undergoes oxidative phos-
phorylation in -cells. Under hyperglycemic conditions,
however, glucose is metabolized via alternative pathways
(33). These pathways include glyceraldehyde autophos-
phorylation, PKC activation, dicarbonyl formation, sor-
bitol metabolism, and hexosamine metabolism, which
produce more ROS than oxidative phosphorylation (34,
35). Changes in glucosemetabolism via these pathways in
RCAN1ox -cells might therefore underlie the increased
ROS production we observed in RCAN1ox islets.
The age of onset of fasting hyperglycemia, glucose in-
tolerance, hypoinsulinemia, islet shrinkage, and the re-
duced expression ofmultiple key-cell genes inRCAN1ox
mice is similar to changes reported inmicedisplayinga loss
of -cell calcineurin activity (10). This indicates that these
changes in RCAN1ox mice may be due to reduced cal-
cineurin activity caused by higher RCAN1 expression.
However, some of the observed differences in RCAN1ox
-cells in mitochondrial size, ROS production, GSIS, and
vesicle filling have not been previously associated directly
with calcineurin activity. Elucidating the pathways under-
lyingRCAN1 regulation of-cell function and identifying
those that are dependent and independent of effects on
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calcineurin activity will be an important area of future
research.
Loss of -cells and ensuing hypoinsulinemia is the ul-
timate cause of both type 1 and type 2 diabetes. In type 1
diabetes, -cell death is caused by sudden autoimmune
destruction. We do not feel this mechanism underlies the
diabetes inourRCAN1oxmousemodel because thesemice
lose-cells after 40–60dandgradually displayworsening
hyperglycemia. In type2diabetes, insulin resistance causes
an increase in -cell number and enables compensatory
hyperinsulinemia to maintain glucose homeostasis in hu-
mans. However, unknown changes, which are associated
with glucotoxicity-induced oxidative stress, lead to an in-
crease in -cell apoptosis, a relative inadequacy of insulin,
poorly controlled blood glucose, and ultimately type 2
diabetes. The finding that chronic, but not acute, hyper-
glycemia induces RCAN1 expression raises the potential
for RCAN1 to be involved in the progressive -cell dys-
function occurring in type 2 diabetes. By contrast, in pri-
mary neuronal cells, the short-term induction of RCAN1
expression is thought to have a protective effect, whereas
prolonged elevated expression has a detrimental effect on
cell survival (36). Our in vivo data illustrate that a chronic
increase in RCAN1 expression leads to -cell loss, hypo-
insulinemia, and diabetes. Although 6 d of high glucose in
WT mice causes a 1.5-fold induction of RCAN1 expres-
sion, the effect of more prolonged hyperglycemia on the
level of RCAN1 expression is unknown. Our RCAN1ox
mouse model has a 3.5- to 5-fold increase in islet RCAN1
expression yet develops hyperglycemia only at 60–70 d of
age.Wehypothesize thatwhenhyperglycemia occurs over
time, as occurs during the progression of both type 1 and
type2diabetes,RCAN1expressionwill increase, resulting
in -cell dysfunction, -cell loss, and hypoinsulinemia.
Our findings, therefore, not only link RCAN1 to the con-
trol of -cell number, secretion, gene expression, and mi-
tochondrial function but also identify that RCAN1 is reg-
ulated by chronic hyperglycemia, and as such, increased
RCAN1 expression has the potential to underlie -cell
dysfunction and hypoinsulinemia in diabetes.
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